S-1: Abpro Holdings Files S-1 for $50M Equity Offering Amid Going Concern Doubts

Abpro Holdings, a biotechnology company, filed an S-1 registration statement for a $50 million standby equity purchase agreement, while facing substantial doubt about its ability to continue as a going concern.

Summary

• Abpro Holdings, Inc. (New Abpro) filed an S-1 registration statement for the resale of up to 9,775,017 shares of Common Stock by YA II PN, Ltd. (YA) under a Standby Equity Purchase Agreement (SEPA).
• The company may receive up to $50 million in gross proceeds from sales to YA under the SEPA, which will be used for working capital and general corporate purposes.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year due to recurring losses and insufficient cash to fund operations and drug development.
• As of June 30, 2025, the company had an accumulated deficit of $123 million and a net loss of $6.8 million for the six months ended June 30, 2025.
• The company's Common Stock and Public Warrants are listed on the Nasdaq Global Market under symbols ABP and ABPWW, respectively, with a closing price of $5.62 for Common Stock on November 6, 2025.
• Abpro is an emerging growth company focused on developing next-generation antibody therapeutics for immuno-oncology and ophthalmology, leveraging its proprietary DiversImmune and MultiMab™ platforms.
• Lead product candidates include ABP-102 for HER2+ solid tumors (breast and gastric cancers) and ABP-201 for vascular diseases of the eye (Wet AMD and DME).
• The company plans to initiate Phase 1/2 clinical trials for ABP-102 in the first half of 2026 and Phase 1 clinical trials for ABP-201 in the second half of 2026.
• Abpro is in breach of its license agreement with MedImmune/AstraZeneca related to ABP-201, but believes it does not need the licensed IP for ABP-201's development.
• The company received multiple Nasdaq delisting notices for failing to meet minimum bid price, market value of publicly held shares (MVPHS), and market value of listed securities (MVLS) requirements.
• A 1-for-30 reverse stock split was effected on October 31, 2025, to regain Nasdaq compliance, reducing outstanding shares from 81.15 million to approximately 2.7 million.
• Research and development expenses decreased by $1.2 million for the six months ended June 30, 2025, compared to the same period in 2024, primarily due to personnel furloughs.
• General and administrative expenses increased by $1.2 million for the six months ended June 30, 2025, due to public company operating costs, partially offset by reduced payroll.
• The company has outstanding legal proceedings, including a $700,000 judgment against it from a CRO vendor and a $1.23 million demand from Memorial Sloan Kettering Cancer Center (MSK) for unpaid license fees.
• An excise tax liability of $4.4 million (including interest and penalties) from ACAB's 2023 share redemptions was assumed by Abpro, which is currently being discussed with the IRS.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including substantial doubt about its going concern ability, significant accumulated deficits, and multiple Nasdaq delisting threats. While it has promising preclinical drug candidates and a potential $50M capital raise facility, the current financial state and operational challenges (e.g., R&D slowdown due to funding, management changes, legal disputes, internal control weaknesses) indicate a highly precarious situation. The potential for dilution from the SEPA and the low stock price relative to warrant exercise prices further underscore the negative outlook.

Positives

• Secured a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. for up to $50 million, providing a potential source of future funding.
• Lead product candidates, ABP-102 (HER2+ solid tumors) and ABP-201 (Wet AMD/DME), are advancing towards clinical trials in 2026.
• ABP-102 has shown promising preclinical in vitro results, demonstrating selective killing of HER2-high and intermediate cancer cells with reduced activity on HER2-low cells, suggesting a favorable safety profile.
• ABP-201, a dual VEGF and ANG-2 inhibitor, has shown comparable reductions in vascular leakage and lesion volume to Eylea in rat models and favorable ocular half-life in preclinical PK models.
• Strategic partnerships are in place with Celltrion Inc. for worldwide development and commercialization of ABP-102, including potential milestone payments up to $1.75 billion and a 50/50 profit split.
• Partnership with Abpro Bio International, Inc. for ABP-201 in specific territories includes potential milestone payments up to $540 million and double-digit percentage royalties.
• The company has a B cell cloning platform for developing neutralizing antibodies against viruses like SARS-CoV-2 and RSV, indicating broader research capabilities.
• An experienced leadership team and scientific advisory board with backgrounds from major pharmaceutical and biotech companies (e.g., Celgene, Moderna, Dana-Farber Cancer Institute, Stanford, Harvard Medical School) are in place.

Negatives

• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year due to ongoing operating losses and lack of financing commitments.
• The company has a history of significant losses, with an accumulated deficit of $123 million as of June 30, 2025, and expects to incur significant losses for the foreseeable future.
• All product candidates are in early preclinical development and have never been tested in human subjects, indicating a high risk of failure and no near-term product revenue.
• The company is in breach of its license agreement with MedImmune/AstraZeneca related to ABP-201, which gives MedImmune/AstraZeneca a termination right.
• Received multiple Nasdaq delisting notices for failing to meet minimum bid price, market value of publicly held shares (MVPHS), and market value of listed securities (MVLS) requirements, indicating significant market and financial challenges.
• The 1-for-30 reverse stock split, while intended to regain Nasdaq compliance, may decrease the liquidity of common stock and not attract new investors.
• The sale of up to 9,775,017 shares by YA, representing approximately 361% of total outstanding Common Stock as of November 6, 2025, could result in significant dilution and a decline in share price.
• The exercise price for Public Warrants ($114.90 per share) is significantly higher than the current Common Stock price ($5.62 on November 6, 2025), making it unlikely for warrant holders to exercise, thus limiting potential cash proceeds.
• The company has identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, insufficient controls for contractual obligations, and lack of formal written policies.
• A restatement of prior period financial statements due to accounting errors (understatement of liabilities under a license agreement) has occurred, potentially affecting investor confidence and raising reputational issues.
• The company is involved in legal proceedings, including a $700,000 judgment from a CRO vendor and a $1.23 million demand from MSK for unpaid license fees, which could increase costs and divert management attention.
• An excise tax liability of $4.4 million (including interest and penalties) from ACAB's 2023 share redemptions was assumed, and the company is unable to pay it in full, leading to additional interest and penalties.

Risks

• Uncertainties around the ability to raise additional capital raise substantial doubt about the ability to continue as a going concern, including drug development.
• Drug development is a highly uncertain undertaking and involves a substantial degree of risk, with product candidates in early stages and never tested in humans.
• The market may not be receptive to product candidates based on novel therapeutic modalities, potentially hindering revenue generation from sales or licensing.
• Substantial additional funds will be needed to advance product candidates, and there is no guarantee of sufficient future funding.
• Breach of the license agreement with MedImmune/AstraZeneca could lead to termination, although the company believes it does not need the licensed IP for ABP-201.
• Collaborations with third parties may not be successful, potentially preventing capitalization on market potential or receipt of milestone/royalty payments.
• Reliance on third parties for preclinical studies and clinical trials poses risks of non-performance, regulatory non-compliance, or missed deadlines, delaying development programs.
• Dependence on third-party manufacturing and supply partners for preclinical and clinical materials could lead to limited, interrupted, or unsatisfactory supply.
• Intense competition from larger, better-funded entities developing novel treatments and technology platforms could adversely affect the ability to commercialize product candidates.
• Inability to attract and retain qualified key management, technical personnel, and employees would impair the ability to implement the business plan.
• Litigation and legal proceedings may substantially increase costs and harm the business, including product liability risks as clinical trials commence.
• Inability to obtain or protect intellectual property rights, or inadequate intellectual property rights, could hinder effective competition.
• Failure to comply with obligations under license, collaboration, or other intellectual property agreements could result in damages or loss of necessary intellectual property rights.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time, and changes in patent law could diminish patent value.
• Inability to protect intellectual property rights throughout the world could negatively impact the business.
• Third parties may initiate legal proceedings alleging infringement, misappropriation, or violation of their intellectual property rights, leading to costly litigation or licensing requirements.
• Inability to protect the confidentiality of trade secrets would harm the business and competitive position.
• Non-compliance with government patent agency requirements could reduce or eliminate patent protection.
• Clinical development is a lengthy, expensive, and unpredictable process with uncertain outcomes, and earlier study results may not predict future trial results.
• Inability to obtain U.S. or foreign regulatory approval would prevent commercialization of product candidates.
• Data from clinical trials conducted outside the United States may not be accepted by the FDA or comparable foreign regulatory authorities.
• Ongoing regulatory obligations and continued regulatory review, even after approval, may result in significant additional expense, labeling restrictions, or market withdrawal.
• Healthcare legislative reform measures may have a material adverse effect on the business and results of operations, including downward pressure on pricing and reimbursement.
• Failure to comply with healthcare laws and regulations could lead to enforcement actions, affecting the ability to develop, market, and sell products.
• Exposure to U.S. and foreign anti-corruption and anti-money laundering laws, with non-compliance leading to criminal/civil liability.
• Comprehensive tax reform bills could adversely affect the business and financial condition.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.
• The Charter and Bylaws' forum selection provisions could limit stockholders' ability to obtain a favorable judicial forum.
• Anti-takeover provisions in governing documents and Delaware law could make an acquisition more difficult or limit stockholders' influence.
• Management team has limited experience managing a public company, potentially diverting attention and increasing expenses.
• Material weaknesses in internal control over financial reporting could affect timely and reliable financial reports and weaken investor confidence.
• Restatement of prior period financial statements may affect investor confidence and raise reputational issues.
• Reduced SEC reporting requirements as an emerging growth company may make shares less attractive to investors.
• An active market for securities may not develop, adversely affecting liquidity and price.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.
• The market price for Common Stock may decline due to various factors, including negative investor reactions or failure to meet analyst expectations.
• Future sales, or the perception of future sales, by the company or current stockholders could cause the market price to decline significantly.
• Warrants may expire worthless or their terms may be amended, and the company may redeem unexpired warrants at a disadvantageous time for warrantholders.
• It is not possible to predict the actual number of shares sold under the SEPA or the gross proceeds, and the company may not have access to the full amount available.

Future Outlook

Abpro Holdings expects to incur substantial operating losses and negative cash flows for the foreseeable future as it advances its preclinical activities and clinical trials for product candidates. The company plans to initiate Phase 1/2 clinical trials for ABP-102 in the first half of 2026 and Phase 1 clinical trials for ABP-201 in the second half of 2026, contingent on future funding. Future funding is expected to come from equity and debt financings, collaboration agreements, and research grants. The company aims to build a fully integrated discovery-to-commercial antibody therapeutics company, expanding its pipeline of CD3-targeting T-cell engagers and other multi-specific antibody constructs.

Management Comments

• Management has concluded there is substantial doubt as to the company's ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued.
• We believe that Mr. Suk's business experience, and his previous service on the board of directors of a public company in the industry, qualify him to serve as a member of the board of directors.
• We believe Mr. Eisenberg's experience in public policy and expertise in private market investments makes him well-qualified to serve on our Board.
• We believe that Mr. Lee's experience in drug development, and his previous service on the board of directors of a pharmaceutical company, qualify him to serve as a member of the board of directors.
• We believe Mr. McDonald's experience as an executive and board member of a publicly traded company and in the bioscience industry makes him well-qualified to serve on our board of directors.
• We believe Mr. Chan's experience on Abpro's board of directors and as Abpro's chief executive officer, as well as his experience in the industry, qualifies him to serve on the board of directors.
• We believe that our proprietary antibody platforms and approach overcome these limitations, however, we have yet to (i) produce antibodies on a scale needed for clinical trials or commercialization or (ii) evaluate any of our product candidates in a patient.
• It is management's belief that ABP-102 has the potential to provide longer lasting or even curative results in a broader set of patients than are currently addressed by HER2-directed therapies.
• We believe the TetraBi antibody format of ABP-102 provides a potentially transformative approach to immuno-oncology.
• We believe a more effective therapy that requires less frequent dosing would address the deficiencies of current therapy and be rapidly adopted as the new standard of care for the treatment of the disease.

Industry Context

The biotechnology and biopharmaceutical industries are highly competitive and characterized by rapid technological evolution. Abpro Holdings operates in the immuno-oncology and ophthalmology sectors, which are significant and growing markets. The global HER2+ market is forecast to reach $12.1 billion by 2030, and the global ophthalmology market is expected to reach $84 billion by 2030. The company's focus on novel bispecific antibodies, particularly T-cell engagers and ligand traps, positions it within a cutting-edge area of drug development. However, the industry is dominated by larger, well-funded multinational companies, and the regulatory approval process for novel therapeutic modalities like bispecific antibodies is complex and lengthy, with limited FDA experience in this specific area. The need for substantial capital for drug development is a common challenge for preclinical stage biopharmaceutical companies.

Comparison to Industry Standards

• ABP-102, a next-generation T-cell engager, aims to improve upon currently approved HER2-targeting agents like Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1) by redirecting cytotoxic T cells and potentially offering longer-lasting or curative results in a broader patient population.
• ABP-201, a dual VEGF and ANG-2 co-targeting agent, is designed to compete with existing standard-of-care treatments for DME and Wet AMD, such as Eylea (aflibercept), Lucentis (ranibizumab), and off-label Avastin (bevacizumab).
• The recent FDA approval of Vabysmo (faricimab), another VEGF and ANG-2 co-targeting agent, with dose-dependent improvement in visual acuity compared to Lucentis, provides strong validation for Abpro's ABP-201 approach.
• Abpro's TetraBi antibody format for ABP-102, with bivalent HER2 binding and functionally monovalent CD3 binding, is presented as an improvement over first-generation Bispecific T-cell Engagers (BiTEs) (which lack an Fc region and require continuous infusion) and second-generation bispecific antibodies (which often have only one binding site for the tumor antigen).
• The company highlights potential advantages of its TetraBi antibodies over CAR T therapy, including simpler administration (intravenous infusion in local clinics), reduced waiting times, no need for chemotherapy to deplete immune cells, easier toxicity management, and lower cost, addressing significant challenges in CAR T adoption for solid tumors.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed by a contract research organization (CRO) vendor on September 12, 2023, for failure to make installment payments under a January 23, 2023 settlement agreement. A judgment was entered on January 24, 2024, awarding the CRO vendor approximately $700,000.
• Memorial Sloan Kettering Cancer Center (MSK) issued a notice of breach in June 2023, followed by a notice of termination in September 2023, demanding payments totaling at least $1,230,000 for services under the MSK License Agreement. The company does not dispute the payment obligations but has not paid to preserve cash and is working to finalize a settlement agreement.
• The company has accrued $325,000 as of June 30, 2025, related to disputed invoices with other vendors.
• The MedImmune License Agreement (now AstraZeneca) for ABP-201 is in breach due to missed IND application (July 2021) and Phase II commencement (December 2022) target dates, giving AstraZeneca a termination right. The company does not expect a material impact if terminated, as it believes it does not need the licensed IP for ABP-201.
• A complaint was received on June 17, 2025, from a former director of Legacy Abpro asserting $748,000 owed for consulting fees, bonuses, and unpaid promissory note principal and interest. The company is planning to discuss the validity of these claims.

Related Party Transactions

• The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (YA) on October 30, 2024, for up to $50 million in equity purchases. YA is a Selling Securityholder.
• On November 14, 2024, the company entered into a Convertible Promissory Note for $3 million with YA, and on June 23, 2025, a Second Convertible Promissory Note for $2 million with YA.
• Abpro Bio International, Inc. (ABI), a significant investor, owns approximately 20.3% of New Abpro. The company has a collaboration and license agreement with ABI for ABP-201.
• ABI made a $30 million equity investment in Abpro's Series E preferred stock in 2020 and an $8 million investment in Series F preferred stock in 2022.
• On October 18, 2023, Abpro entered into a promissory note agreement with ABI for up to $6 million, which was partially repaid through conversion into common shares in the PIPE Financing.
• On October 7, 2024, Abpro entered into an additional promissory note with ABI for up to $1 million, which was repaid at the Closing from PIPE Financing proceeds.
• Promissory notes were issued on December 29, 2023, to Ian Chan (executive) for $176,000 and Eugene Chan (former director) for $124,000 for deferred bonuses. $150,000 was paid towards these notes at Closing.
• On April 18, 2024, a promissory note agreement was entered into with an executive (Ian Chan) for up to $2.158 million in funding, which was converted into 20,000 shares of common stock at Closing.
• On February 7, 2025, 28,333 warrants (Ian Chan Warrants) were issued to Ian Chan in satisfaction of the agreement to issue stock options or warrants related to the April 18, 2024 promissory note.
• On August 16, 2024, Abpro issued a promissory note for a $103,000 bridge loan from Shahraab Ahmad, CEO of ACAB, which was cancelled and replaced with a promissory note to ACAB at Closing.
• On November 21, 2024, a severance payment of $221,000 was made to an executive, superseding all other agreements.
• On December 24, 2024, a payment of $574,000 was made to Atlantic Coastal Acquisition Management II LLC (the Sponsor) in accordance with the Merger Agreement.
• On July 25, 2025, the CEO Consulting Agreement was signed with BioCelsus International Inc., an entity wholly owned by the CEO (Miles Suk), for an annual base fee of $300,000 and 16,667 RSUs.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from the potential sale of up to 9,775,017 shares by YA, representing 361% of current outstanding shares. The 1-for-30 reverse stock split also reduced the number of outstanding shares, potentially affecting liquidity. The low market price of common stock ($5.62) compared to warrant exercise prices ($114.90) means warrants are unlikely to be exercised, limiting potential cash infusion for the company. The Nasdaq delisting threats pose a risk to the stock's trading liquidity and market price. The company's going concern doubt indicates a high risk of investment loss.
• **Employees:** The company furloughed its Chief Medical Officer, Dr. Markelewicz, with employment termination effective November 30, 2025, indicating potential instability or restructuring. Reduced R&D activities due to capital raising efforts could impact job security and morale for research personnel. The company's ability to attract and retain qualified personnel is a stated risk.
• **Customers/Patients:** The delay in advancing product candidates to clinical trials due to funding issues means potential new therapies for severe and life-threatening diseases (HER2+ cancers, Wet AMD, DME) will be delayed. The success of novel antibody constructs is uncertain, impacting future treatment options.
• **Creditors:** The company has significant current liabilities, including a $700,000 judgment from a CRO vendor, a $1.23 million demand from MSK, and a $4.4 million excise tax liability. The 'going concern' doubt raises concerns about the company's ability to meet its financial obligations.
• **Partners (Celltrion, Abpro Bio, NJCTTQ):** The company's financial instability and R&D slowdown could impact the progress and success of collaborative development programs, potentially delaying milestone payments and future profit splits. The breach of the MedImmune/AstraZeneca license agreement, while deemed immaterial by Abpro, could still affect partner confidence.

Next Steps

• Initiate Phase 1/2 clinical trial of ABP-102 for HER2+ breast and gastric cancers in the first half of 2026.
• Advance ABP-201 into Phase 1 clinical trials for Wet AMD in the second half of 2026, contingent on future funding.
• Conduct IND-enabling studies for lead product candidates in preparation for final GLP toxicity studies and GMP manufacturing.
• Request Pre-IND meetings with the FDA when appropriate for lead product candidates.
• Rapidly follow ABP-102 with a broad pipeline of CD3-targeting T-cell engagers and leverage this approach to other immune cell targets.
• Continue investing in DiversImmune and MultiMab™ platforms to expand the collection of antibody building blocks and apply engineering approaches.
• Evaluate toxicity of ABP-150 in a non-human primate model, with clinical trials expected in the first half of 2027.
• Initiate clinical trials for ABP-110 in the first half of 2027.
• Continue to explore and execute strategic collaborations for development and commercialization.
• Build a leading fully integrated discovery-to-commercial antibody therapeutics company by complementing discovery/development strengths with clinical expertise and commercial capabilities.
• Regain compliance with Nasdaq's Minimum Bid Price, MVPHS, and MVLS requirements, with a hearing before an appeal panel scheduled for October 30, 2025.
• Address material weaknesses in internal control over financial reporting by enhancing authorization procedures, access controls, and formalizing written policies.
• Engage in discussions with Mabwell regarding the validity of their $3.3 million claim for development milestones.
• Engage with the IRS to determine a payment plan for the $4.4 million excise tax liability and reconcile the disputed amount.

Key Dates

Recommendation

Abpro Holdings is in a highly precarious financial position, explicitly stating 'substantial doubt about its ability to continue as a going concern.' This fundamental uncertainty, coupled with recurring significant net losses ($6.871M in H1 2025), critically low cash reserves ($2.014M as of June 30, 2025), and multiple Nasdaq delisting notices, paints a dire picture. While the $50M SEPA offers a potential lifeline, it comes with substantial dilution risk (9.775M shares, 361% of current float) and its full utilization is uncertain. The recent 1-for-30 reverse stock split is a clear indicator of severe share price depreciation and does not fundamentally address the underlying business challenges. All product candidates are preclinical, meaning no near-term revenue from product sales, and R&D has slowed due to funding constraints. Significant legal liabilities and internal control weaknesses further compound the risks. Given the overwhelming financial instability, high operational risks, and severe dilution potential, a seasoned investor would likely recommend a strong sell to mitigate further losses.

Keywords

Biotechnology, Antibody Therapeutics, Immuno-oncology, Ophthalmology, HER2+ Cancer, Wet AMD, Diabetic Macular Edema, SEC Filing, S-1 Registration, Standby Equity Purchase Agreement, Going Concern, Nasdaq Delisting, Reverse Stock Split, Clinical Trials, Drug Development, ABP-102, ABP-201, Celltrion, AstraZeneca, Intellectual Property, Financial Reporting, Capital Raise